What is HC Wainwright’s Estimate for Evolus FY2025 Earnings?

Evolus, Inc. (NASDAQ:EOLS) – Research analysts at HC Wainwright decreased their FY2025 earnings per share estimates for shares of Evolus in a research note issued on Wednesday, March 5th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($0.23) per share for the year, down from their previous estimate of $0.11. HC Wainwright currently has a “Buy” rating and a $27.00 target price on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for Evolus’ FY2026 earnings at $0.49 EPS, FY2027 earnings at $1.16 EPS, FY2028 earnings at $2.35 EPS and FY2029 earnings at $3.81 EPS.

A number of other analysts have also commented on the company. Barclays lifted their price target on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Evolus in a research note on Wednesday, March 5th.

Evolus Stock Up 0.6 %

Shares of NASDAQ EOLS opened at $13.58 on Monday. The stock’s fifty day moving average is $12.95 and its 200 day moving average is $14.05. The stock has a market capitalization of $863.51 million, a P/E ratio of -14.92 and a beta of 1.28. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. Evolus has a 52 week low of $9.25 and a 52 week high of $17.82.

Institutional Trading of Evolus

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Creative Planning increased its stake in Evolus by 23.7% in the 3rd quarter. Creative Planning now owns 15,451 shares of the company’s stock worth $250,000 after acquiring an additional 2,963 shares during the last quarter. GSA Capital Partners LLP lifted its holdings in Evolus by 335.3% in the 3rd quarter. GSA Capital Partners LLP now owns 120,964 shares of the company’s stock worth $1,960,000 after buying an additional 93,176 shares during the period. Oppenheimer & Co. Inc. purchased a new stake in Evolus in the 3rd quarter worth approximately $212,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Evolus in the 3rd quarter worth approximately $940,000. Finally, Intech Investment Management LLC purchased a new stake in Evolus in the 3rd quarter worth approximately $228,000. 90.69% of the stock is currently owned by institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.